KKR will partner with LGC to provide capital and operational support to facilitate future growth.
LGC provides a range of measurement products and services which underpin the safety, health and security of the public, including reference materials and proficiency testing, genomics reagents, instrumentation and services and expert sample analysis and interpretation. The company serves customers across a number of end markets including pharmaceuticals, agricultural biotechnology, food, environment, government and academia.
LGC has grown over the past five years through significant investment support from Bridgepoint that has enabled, for example, the acquisition of 12 related companies and revenue growth from £130 million ($143 million) in 2010 to £222 million ($244 million) in 2015. With the support of KKR, management plans to continue the rapid development of the business, building global leadership positions within their chosen markets, with a particular focus on the U.S. and Asia.
Founded in 1976, KKR is a global investment firm with $100 billion in assets under management, and currently owns 94 actively managed companies generating aggregate total revenues of more than $200 billion. KKR has a long history of success in healthcare exemplified by investments such as Alliance Boots, Adocia, HCA, Jazz Pharmaceuticals, Panasonic Healthcare and PRA International.
Chris Busby, the partner responsible for Bridgepoint’s investment activities in the U.K., said, “When LGC was privatized in 1996, it had one client in one geography. Having performed strongly under our five-year ownership, now it has a blue chip global customer base of over 20,000 customers in 150 countries. As the business has grown, LGC has tripled profits, almost doubled revenues, built a demonstrable IP portfolio and completed 12 acquisitions.”
LGC, whose headquarters are near London, employs more than 2,200 employees across 22 countries. Since its privatization in 1996, the company has maintained strong links with the U.K. government and developed a thriving private-sector business.
The investment in LGC will be made primarily by the KKR European Fund IV.